Key clinical point: The interleukin-1 alpha inhibitor improved both pain and lesion count in patients regardless of prior treatment with an antitumor necrosis factor agent.
Major finding: Cleared lesions and improved pain in more than 60% of patients who received it.
Study details: The 12-week proof-of-concept study comprised 42 patients.
Disclosures: XBiotech is developing the drug and sponsored the study. Dr. Gottlieb was an investigator and designed the protocol, but did not receive compensation for her work.
REPORTING FROM AAD 2019
Must Reads in Medical Dermatology
List of medications linked to drug-induced lupus expands, Arnaud L et al. Ann Rheum Dis. 2019 Feb 4. doi: 10.1136/annrheumdis-2018-214598
Incidence of Skin Diseases by Age Group Examined, Int J Dermatol; 2018 Sep; Wessman, et al